TEM8/ANTXR1 upregulation has been described in a variety of solid tumors types including triple negative breast cancer (Xu et al., 2021), prostate cancer (Li et al., 2021a), gastric cancer (Li et al., 2021b; Sun et al., 2021), pancreatic cancer (Alcalá et al., 2019), angiosarcoma (Kusaba et al., 2021), colon cancer (Ł et al., 2021), and NSCLC (Gong et al., 2021). Here, ANTXR1 is linked to triple-negative breast carcinoma.